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SUMMARY 
 
A randomized single-blind, double-observer trial was performed to evaluate the efficacy 
of a new non-steroidal anti-inflammatory analgesic drug, ketorolac, in the treatment of 
post-orthopaedic surgery pain. Sixty patients with moderate to severe pain were studied; 
30 patients were treated with ketorolac at a dose of 30 mg intramuscularly up to 4-times 
a day, whilst the other 30 patients received 0.3 mg buprenorphine intramuscularly up to 
4-times a day. A significant reduction in the severity of the pain was recorded in both 
groups. Throughout the study, comparable efficacy was found between the two 
therapies although buprenorphine showed greater efficacy during the first 8 hours. 
Interestingly, the withdrawals due to adverse events were significantly lens in the 
ketorolac group (p < 0.001). This study, therefore, suggests that ketorolac may be a 
useful and more acceptable alternative to buprenorphine in the treatment of post-
orthopaedic surgery pain. 
 
 
 
KEY WORDS 
 
Ketorolac, buprenorphine, analgesics, pain, post-operative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
After surgery, most patients require analgesic medication. These analgesics should be 
chosen carefully to balance the benefits of their efficacy with the potential for side-
effects which such drugs may cause. At present, opioids are the mainstay of analgesic 
treatment but are controlled drugs in most countries; these stringent controls delay their 
administration and increase nursing workloads. 
 
Ketorolac is a new non-steroidal anti-inflammatory drug.
3
 Its chemical name is (±)-5-
benzoy1-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, 2-amino-2-(hydroxy-methyl)-
1,3-propanediol. Ketorolac is also a powerful analgesic and as such it presents a 
potentially useful and more acceptable alternative to opiates for the relief of moderate 
and severe pain.
7
 Its analgesic action is mostly attributable to its ability to inhibit the 
cyclo-oxygenase enzymes involved in prostaglandin synthesis.
7
 Ketorolac is well 
absorbed after oral administration and has an excellent tolerance profile.
1.4-6
 It is without 
opioid side-effects (or any demonstrable opiate receptor binding)
2
 and thus has no 
addictive potential. 
  
The present study was designed to evaluate the efficacy of intramuscular ketorolac 
therapy for the treatment of pain, and compare this with buprenorphine in a single-blind 
trial in surgical patients. 
 
 
 
PATIENTS AND METHODS 
 
Sixty patients, of either sex, aged 18 to 70 years, suffering moderate to severe pain after 
orthopaedic surgery (total hip replacement, lumbar arthrodesis) were enrolled in the 
study. Patients with significant impairment of brain, liver, kidney, lung or heart function 
were excluded, as were those displaying perturbed endocrine function or having gastric 
or duodenal ulcers. Patients with a history of asthma, allergy to salicylates or non-
steroidal anti-inflammatory drugs in general, patients known to be hypersensitive to 
buprenorphine, addicted to alcohol or other drugs, and pregnant or nursing women were 
also excluded. 
 
Patients had to give verbal informed consent to participate in the study and were then 
randomly allocated to receive 30 mg intramuscular ketorolac up to 4-times a day or 0.3 
mg intramuscular buprenorphine up to 4-times a day. Rescue medication of 30 mg 
pentazocine was available, if required. No pentazocine was allowed within the first 2 
hours after the initial dose of the trial drug. No analgesics or drugs binding strongly to 
plasma proteins were allowed in the 6 hours before the commencement of the study. 
Treatment continued for 3 days. 
 
Patients underwent a medical examination before entry into the study. Immediately 
before the first dose of study drug they were questioned as to the severity of their pain. 
Pain was evaluated on a 100 mm visual analogue scale, marked ‘no pain’ at one end (0 
mm) and ‘very severe’ pain at the other (100 mm). The patients were re-examined 30 
minutes after receiving the first dose and then hourly for the first 8 hours of the study. 
At each assessment time, patients were asked to rate the severity of their pain and also 
to assess pain relief, again using a similar visual analogue scale, marked ‘no relief’ at 
one end (0 mm) and ‘complete relief’ at the other end (100 mm). Subsequently, they 
were evaluated at the end of each treatment day, when pain severity and pain relief were 
evaluated using the same visual analogue scale evaluation. At the end of each study day 
and at the end of the study, both patients and investigators provided an overall 
evaluation of the efficacy of treatment rating it as excellent, very good, good, fair or 
poor. Pain at the injection site was also evaluated each day, 8 and 24 hours after 
administering the first injection on that day, and measured according to the following 
scale: no pain, mild pain, moderate pain or severe pain. Adverse events were reported 
spontaneously by the patient at each monitoring time or recorded by the investigator, 
using indirect questioning. 
 
Scores for analogue pain intensity difference (APID) were calculated as the difference 
between the initial pain intensity and the subsequent half-hour or hourly value. The sum 
of analogue pain intensity differences, calculated as the area under the APID by time 
curve (SAPID), and the maximum APID during the 8-hour period, were calculated for 
each patient, as was the area under the analogue pain relief score by time curve 
(TOTAPAR). 
  
 
Statistical analysis 
 
A descriptive statistical analysis was performed for each variable and both treatment 
groups were analyzed to confirm their comparability at the commencement of the study. 
Student's and Mann Whitney's U tests were used for the quantitative variables, and the 
Pearson's χ2-test was used for qualitative variables. 
 
Within-group efficacy was analyzed using non-parametric tests for paired data; these 
analyses were performed to study the changes in clinical signs, over time, within each 
treatment group. The main part of the statistical analysis focused on evaluating 
differences in efficacy and tolerance between treatment groups, using the Mann-
Whitney test for quantitative variables and contingency tables (χ2-test with Yates' 
correction when necessary) for qualitative variables. Results were considered 
statistically significant for p < 0.05. 
 
 
RESULTS 
 
A total of 60 patients was enrolled of whom 30 received ketorolac and 30 received 
buprenorphine. There were 2 protocol violators, 1 in each treatment group, who took 
medication which was not allowed. The remaining 58 patients were included in the 
analyses. The two groups of patients were comparable in terms of age, sex, weight and 
severity of pain before the study commenced (Table I). 
 
During the first 6 hours after the initial dose of study drug, statistically significant 
differences favouring buprenorphine were found for SAPID at 3 hours (p=0.0440), 
SAPID at 6 hours (p = 0.0300), TOTAPAR at 3 hours (p = 0.0259) and TOTAPAR at 6 
hours (p=0.0134), (Table II). However, ‘time to first positive APID’ and ‘time to peak 
APID’ were not statistically different between the groups, indicating a similar time to 
onset of action. Similarly, there was not a significant difference between the groups 
with respect to peak APID, indicating a comparable reduction in pain scores (Table III). 
The daily evaluation of pain severity at the end of Days 1, 2 and 3 showed no 
statistically significant differences between the two treatments, nor were there 
significant differences in pain relief at the end of Days 1 or 3, although pain relief at the 
end of Day 2 was significantly greater in the buprenorphine group. 
  
The study medication was given on an ‘as needed’ basis and a comparison was made 
between the number of doses administered in each treatment group. The average 
number of doses on the first day was 2.88 for ketorolac and 2.74 for buprenorphine; on 
the second day, the number was 2.62 for ketorolac and 2.21 for buprenorphine, and on 
the third day, 0.69 for ketorolac and 0.95 for buprenorphine. These were not statistically 
significantly different on any of the study days. 
 
According to the investigator's and patient's daily overall assessment of efficacy, no 
statistically significant differences were observed between the treatment groups. 
Similarly, the final global assessment of efficacy, by both investigator and patient, 
revealed no significant differences between the treatments. 
 
The differences in the number of patients completing the study in each treatment group 
were not statistically significant (p = 0.7590); however, there was a considerable 
difference in the number of withdrawals due to absence of pain (20 in the ketorolac 
group and 10 in the buprenorphine group) (Table IV). There was also a statistically 
significant difference in the number of patients withdrawing due to adverse events; only 
1 (3.4%) of 29 patients treated with ketorolac and 11 (37.9%) of 29 patients treated with 
buprenorphine were withdrawn from the study due to adverse events (p < 0.001). 
 
Similarly, the total number of patients reporting adverse events was considerably less in 
the ketorolac group (Table V). A total of 7 ketorolac patients reported adverse events, 1 
of whom complained of moderate malaise and discontinued the treatment. Of the 
remaining 6 patients, their complaints were mostly mild, and consisted of nausea (3 
patients), drowsiness (1 patient), headache (1 patient), and gastro-intestinal pain (1 
patient). 
 
In the buprenorphine group, 21 patients reported adverse events, 11 of whom 
discontinued the treatment. The adverse reactions amongst the patients who withdrew 
were nervous system complaints, somnolence, dizziness, drowsiness, confusion, nausea 
and vomiting. Some patients experienced more than 1 event. The pattern of adverse 
events reported by patients who continued in the study was similar to the above, but less 
severe. 
 
 
 
DISCUSSION 
 
The immediate post-operative period is characterized by the highest levels of pain 
experienced by surgical patients. It is during this time that a potent, fast acting 
intramuscular analgesic is needed. The choice of an analgesic drug is always balanced 
by the risk/benefit ratio. The physician has to choose an efficacious drug with the best 
adverse effects profile. The use of a narcotic in this situation is highly effective but a 
drawback to its use is the high incidence of side-effects and its potential for abuse.
8-10
 
 
In this study, 30 mg ketorolac up to 4-times a day as needed, was compared to 0.3 mg 
buprenorphine up to 4-times a day, in order to assess comparative efficacy and 
tolerance. The results of this study indicate that ketorolac is an appropriate choice for 
the treatment of moderate to very severe pain in the early post-operative period and that 
it compares favourably with buprenorphine in efficacy, and was better tolerated. 
 
An important issue in the evaluation of an analgesic agent indicated for post-operative 
pain is the speed with which its analgesic effect is manifested. Rapid onset of action has 
traditionally been considered an important attribute of the narcotic analgesics such as 
buprenorphine. Analysis of the onset of analgesic activity in this study revealed that this 
feature is virtually identical for ketorolac (31.2 minutes) and buprenorphine (30 
minutes). Although in the first 8-hour period buprenorphine resulted in a significant 
lower pain intensity and higher pain relief, scores at the end of each study day showed 
no statistically significant differences between the two treatments, except with respect to 
pain relief which was better in the buprenorphine group at the end of Day 2. Of more 
importance to the clinical situation than the actual pain scores at a particular time is the 
overall view of the treatment, which in this study was assessed at the end of each day 
and at the end of the study. There were no differences between the treatments regarding 
the patients' and the investigator's opinion. 
 
With respect to the tolerability, the complaints were mainly related to the nervous 
system and the digestive system. There were marked differences between the 
treatments. In the ketorolac group, 24% of patients reported adverse events and for 
buprenorphine-treated patients, 72.4% reported adverse events. There were also fewer 
withdrawals due to adverse events (3% with ketorolac and 38% with buprenorphine). 
 
Overall, the results of this study show that 30 mg intramuscular ketorolac up to 4-times 
a day as needed is efficacious in the treatment of moderate to severe post-orthopaedic 
surgery pain. In this setting, ketorolac compares favourably with 0.3 mg buprenorphine 
up to 4-times a day as needed, both in analgesic potency and in rapidity of onset, and is 
associated with a statistically significantly better tolerability profile (p<0.01). 
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Table 1. Details of the patients studied: number of patients and mean (±S.D.) values 
Patients Ketorolac Buprenorphine 
No. studied 29 29 
Sex: Male 12 17 
 Female 17 12 
Age (years) 47.17 ± 16.99 41.34 ± 14.57 
Weight (kg) 64.69 ± 8.99 70.10 ±
 
11.87 
Height (cm) 162.52 ± 9.12 167.48 ± 8.49 
Anaesthesia:   
 General 26 23 
 Other 3 6 
Baseline pain intensity (mm) 69.7 ± 16.9 74.0 ± 16.5 
 
 
 
Table 2. Assessments of treatment efficacy during the first 6 hours: mean values 
Assessment Ketorolac (n = 29) Buprenorphine (n = 29) P value 
SAPID    
After 3 hours 149.6 176.1 0.0440 
After 6 hours 314.1 372.9 0.0300 
TOTAPAR    
After 3 hours 234.8 249.5 0.0259 
After 6 hours 492.4 526.0 0.0134 
 
 
 
Table 3. Assessment of peak analogue pain intensity difference (APID): mean values 
Assessment Ketorolac (n = 29) Buprenorphine (n = 29) P value 
Time to first positive 
APID (hours) 
0.52 0.50 0.3173 
Time to peak APID 
(hours) 
2.40 2.16 0.1550 
Peak APID (mm) 60.4 67.8 0.1456 
Table 4. Reasons for patients withdrawing from the study: number of patients 
Reason Ketorolac (n = 29) Buprenorphine (n = 29)  
No further pain 20 10 
Adverse events 1* 11 
Lack of efficacy 1  
Patient request 1  
* p < 0.001, difference between groups 
 
  
 
Table 5. Summary of adverse events reported: number of patients  
Adverse events Ketorolac (n = 29) Buprenorphine (n = 29)  
No. patients reporting 7 21 
No. patients reporting:   
No events 22 8 
1 event 7 8 
2 events  10 
3 events  3 
Total no. events reported 7 37 
No. patients discontinuing 
because of adverse events 
1 11 
 
 
 
 
